



## OTOİMMÜN PANKREATİT

Ümit KARAOĞULLARINDAN<sup>1</sup>

### GİRİŞ

Otoimmün pankreatit (OİP) kronik pankreatitin nadir bir formu olup, kendine has klinik, patolojik, serolojik ve görüntüleme özelliklerine sahiptir. OİP, kronik pankreatitin otoimmün aracılı mekanizmalarla oluşan özel bir türünü oluşturmaktadır. Literatürdeki ilk vaka 1961 yılında Sarles ve ark.'nın tanımladığı alkolle ilişkisi olmayan muhtemelen otoimmün mekanizmaların eşlik ettiği hipergamaglobülinemi ile seyreden vaka-

dır (1). Bu vakadan sonra 1995 yılında Yoshida ve ark. "otoimmün pankreatit" kavramı ile eşleşen kronik pankreatit klinik antitesini ortaya atmışlardır (2). Geçmişte sklerozan pankreatitis ve nonalkolik dekstrüktif pankreatitis gibi isimlerle de isimlendirilmiştir (3,4). Literatürdeki ilk vakalar Japonya'dan olmakla beraber hastalığı tanımlayan kriterlerdeki gelişme insidansın artmasını Kore, Amerika Birleşik Devletleri (USA) ve Avrupadan da yeni vakaların literatüre girmesini sağlamıştır (5,6). Süregelen zaman içinde son

**Tablo 1. Tip 1 ve Tip 2 otoimmün pankreatitin karşılaştırılması.**

Karakteristik Özellik	Tip 1 Otoimmün Pankreatit	Tip 2 Otoimmün Pankreatit
Etnik köken	Asyada belirgin	Avrupada belirgin
Yaş	60 yaş veya daha yaşlı bireyler	Bir dekat daha gençlerde
Cinsiyet	Erkek dominant	Erkek kadın eşit tutulum
Klinik semptomlar	Obstrüktif sarılık sık abdominal ağrı nadir	Obstrüktif sarılık ve abdominal ağrı yaygın
Serolojik markerlar	Sıklıkla yüksek serum IgG4 ve otoantikor pozitifliği mevcut	Çoğunlukla normal IgG4 düzeyleri ve negatif otoantikorlar
Histopatoloji	Lenfosit ve plazmosit infiltrasyonu, fibrozis IgG4 plazma hücreleri ile infiltrasyon	Granülosit epitelyal lezyonlar ile pankreatik kanalın obliterasyonu ve destrüksiyonu
Ekstrapankreatik organ tutulumu	Sık ve yaygın	Nadir tutulum
İnflamatuar barsak hastalığı beraberliği	Nadir	Sık
Nüks oranı	Yüksek	Düşük
Tanı için histolojik gereklilik	Gerek yok	Gerek var

<sup>1</sup> Dr. Öğr. Üyesi., Çukurova Üniversitesi, Tıp Fakültesi İç Hastalıkları AD. umit2462@hotmail.com

## KAYNAKLAR

1. Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas--an autonomous pancreatic disease?: *Am J Dig Dis* 1961;6:688-98.
2. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis: *Dig Dis Sci* 1995;40(7):1561-8.
3. Garber T, Farrell TJ. Autoimmune pancreatitis: Time for a single nomenclature (abstract). *Gastroenterology* 2004;126(Suppl 2):255.
4. Dimagno EP. Autoimmune chronic pancreatitis: a plea for simplification and consistency: *Clin Gastroenterol Hepatol* 2003;1:421.
5. Okazaki K. Autoimmune pancreatitis is increasing in Japan: *Gastroenterology* 2003; 125:1557.
6. Kim KP, Kim MH, Lee SS, Seo DW, Lee SK. Autoimmune pancreatitis: it may be a worldwide entity: *Gastroenterology* 2004; 126:1214.
7. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology: *Pancreas* 2011;40:352-8.
8. Kanno A, Nishimori I, Masamune A, Kikuta K, Hirota M, Kuriyama S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan: *Pancreas* 2012;41:835-9.
9. Sugumar A, Klöppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications for its diagnosis: *Am J Gastroenterol* 2009;104:2308-10;quiz 2311.
10. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. *Pancreas* 2011;40:809-14.
11. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. *The Lancet* 2015;385(9976): 1460-71.
12. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol* 2012;25(9):1181-92.
13. Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer: *Clin Gastroenterol Hepatol* 2009;7(10):1097-103.
14. Cornell LD, Chicano SL, Deshpande V, Collins AB, Selig MK, Lauwers GY, et al. Pseudotubulointerstitial nephritis associated with autoimmune pancreatocentric disease: *Am J Surg Pathol* 2007;31(10):1586-97.
15. Kawa S, Okazaki K, Kamisawa T, Kubo K, Ohara H, Hasebe O, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis. *Journal of Gastroenterology* 2014;49(5):765-84.
16. Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multi-centre, international analysis. *Gut* 2013; 62(12):1771-6.
17. Cai O, Tan S. From Pathogenesis, Clinical Manifestation, and Diagnosis to Treatment: An Overview on Autoimmune Pancreatitis. *Gastroenterol Res Pract* 2017;2017:3246459.
18. Meng Q, Xin L, Liu W, Lin H, Tian B, Wang L, et al. Diagnosis and treatment of autoimmune pancreatitis in China: a systematic review. *PLoS ONE* 2015;10(6):e0130466.
19. Milosavljevic T, Kostic-Milosavljevic M, Jovanovic I, Krstic M. Extraintestinal manifestations of autoimmune pancreatitis. *Dig Dis* 2012;30(2):220-3.
20. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. *Modern Rheumatology* 2012;22(1):1-14.
21. Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Stone. "Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. *Arthritis Care Res (Hoboken)* 2010;62(9): 1312-8.
22. Ikeura T, Miyoshi H, Shimatani M, Uchida K, Takaoka M, Okazaki K. Long-term outcomes of autoimmune pancreatitis. *World J Gastroenterol* 2016;22(34):7760-6.
23. Kawa S, Okazaki K, Notohara K, Watanabe M, Shimosegawa T. Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. *J Gastroenterol* 2015;50(7):805-15.
24. Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society, "Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society," *Journal of Japan Pancreas Society*, 2002;17: 585-7.

25. Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I, et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. *J Gastroenterol* 2006;41(7):626-31.
26. Kwon S, Kim MH, Choi EK. The diagnostic criteria for autoimmune chronic pancreatitis: it is time to make a consensus. *Pancreas* 2007; 34(3):279-86.
27. Otsuki M, Chung JB, Okazaki K, Kim MH, Kamisawa T, Kawa S, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea symposium on autoimmune pancreatitis. *J Gastroenterol* 2008;43(6):403-8.
28. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, et al. Diagnosis of autoimmune pancreatitis: the Mayo clinic experience. *Clin Gastroenterol Hepatol* 2006;4(8): 1010-6.
29. Ghazale A, Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and indistinguishing it from pancreatic cancer. *Am J Gastroenterol* 2007; 102(8):1646-53.
30. Tabata T, Kamisawa T, Takuma K, Anjiki H, Egawa N, Kurata M, et al. Serum IgG4 concentrations and IgG4-related sclerosing disease. *Clin Chim Acta* 2009;408(1-2):25-8.
31. Song TJ, Kim MH, Moon SH, Eum JB, Park DH, Lee SS, et al. The combined measurement of total serum iga and IgG4 may increase diagnostic sensitivity for autoimmune pancreatitis without sacrificing specificity, compared with IgG4 alone. *Am J Gastroenterol* 2010;105(7):1655-60.
32. Hao M, Li W, Yi L, Yu S, Fan G, Lu T, et al. Hybrid kappa/lambda antibody is a new serological marker to diagnose autoimmune pancreatitis and differentiate it from pancreatic cancer. *Sci Rep* 2016;6:27415.
33. Frulloni L, Lunardi C, Simone R, Dolcino M, Scatoloni C, Falconi M, et al. Identification of a novel antibody associated with autoimmune pancreatitis. *N Engl J Med* 2009;361(22): 2135-42.
34. Kino-Ohsaki J, Nishimori I, Morita M, Okazaki K, Yamamoto Y, Onishi S, et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. *Gastroenterology* 1996; 110(5):1579-86.
35. Kim KP, Kim MH, Song MH, Lee SS, Seo DW, Lee SK. Autoimmune chronic pancreatitis. *Am J Gastroenterol* 2004;99(8):1605-16.
36. Iwashita T, Yasuda I, Doi S, Ando N, Nakashima M, Adachi S, et al. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. *Clin Gastroenterol Hepatol* 2012;10(3):316-22.
37. Kanno A, Ishida K, Hamada S, Fujishima F, Unno J, Kume K, et al. Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. *Gastrointest Endosc* 2012;76(3):594-602.
38. Shigekawa M, Yamao K, Sawaki A, Hara K, Takagi T, Bhatia V, et al. Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? *J Hepatobiliary Pancreat Sci* 2010;17(3):269-74.
39. Lee TY, Kim MH, Park DH, Seo DW, Lee SK, Kim JS, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. *AJR Am J Roentgenol* 2009;193(2):343-8.
40. Sureka B, Rastogi A. Autoimmune pancreatitis. *Pol J Radiol* 2017;82:233-9.
41. Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, et al. International consensus for the treatment of autoimmune pancreatitis. *Pancreatol* 2017;17(1): 1-6.
42. Majumder S, Takahashi N, Chari ST. Autoimmune pancreatitis. *Dig Dis Sci* 2017;62(7): 1762-9.
43. Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. *J Gastroenterol* 2014;49(6):961-70.
44. Okazaki K, Uchida K. Autoimmune pancreatitis: the past, present, and future. *Pancreas* 2015;44(7):1006-16.
45. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. *Gut* 2009;58(11):1504-7.
46. Hirano K, Tada M, Isayama H, Sasahira N, Umefuno G, Akiyama D, et al. Outcome of long-term maintenance steroid therapy cessation in patients with autoimmune pancreatitis: a prospective study. *J Clin Gastroenterol* 2016;50(4):331-7.
47. Masamune A, Nishimori I, Kikuta K, Tsuji I, Mizuno N, Iiyama T, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. *Gut* 2017;66(3):487-94.